NanoViricides shares are trading higher. The company announced it continued to advance its NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a treatment for Ebola in DR Congo.

Benzinga Newsdesk www.benzinga.com Positive 92.4%

Neg 0% Neu 0% Pos 92.4%

Comments

No comments yet. Be the first!